Maryland State Retirement & Pension System Increases Stake in Boston Scientific Corporation $BSX

Maryland State Retirement & Pension System raised its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 4.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 71,745 shares of the medical equipment provider’s stock after buying an additional 3,059 shares during the quarter. Maryland State Retirement & Pension System’s holdings in Boston Scientific were worth $7,706,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in BSX. 1248 Management LLC purchased a new stake in Boston Scientific during the 1st quarter valued at approximately $26,000. Y.D. More Investments Ltd bought a new stake in Boston Scientific in the 1st quarter worth approximately $27,000. Sound Income Strategies LLC increased its stake in Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 120 shares during the last quarter. Oliver Lagore Vanvalin Investment Group bought a new stake in Boston Scientific in the 2nd quarter worth approximately $37,000. Finally, Activest Wealth Management increased its stake in Boston Scientific by 6,216.7% in the 1st quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock worth $38,000 after acquiring an additional 373 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Stock Up 0.9%

NYSE:BSX opened at $96.73 on Thursday. Boston Scientific Corporation has a twelve month low of $80.64 and a twelve month high of $109.50. The company has a market cap of $143.33 billion, a price-to-earnings ratio of 57.58, a price-to-earnings-growth ratio of 2.31 and a beta of 0.61. The stock has a fifty day simple moving average of $102.34 and a 200-day simple moving average of $101.96. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same period last year, the company earned $0.62 earnings per share. The business’s revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on BSX. Oppenheimer raised Boston Scientific from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $118.00 to $125.00 in a research note on Monday, September 8th. Evercore ISI reduced their price objective on Boston Scientific from $115.00 to $110.00 and set an “outperform” rating on the stock in a research note on Tuesday. Jefferies Financial Group reaffirmed a “hold” rating on shares of Boston Scientific in a research note on Monday, July 21st. Leerink Partners lifted their price objective on Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 1st. Finally, Canaccord Genuity Group increased their price target on Boston Scientific from $131.00 to $132.00 and gave the company a “buy” rating in a report on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $120.71.

Insider Transactions at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $18,659,923.46. This represents a 21.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Yoshiaki Fujimori sold 2,901 shares of the stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the transaction, the director directly owned 2,081 shares in the company, valued at $222,646.19. The trade was a 58.23% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 174,214 shares of company stock worth $17,972,457 over the last quarter. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.